Integra LifeSciences (NASDAQ:IART) Cut to Buy at Wall Street Zen

Wall Street Zen cut shares of Integra LifeSciences (NASDAQ:IART) from a strong-buy rating to a buy rating in a report published on Saturday morning.

Other research analysts also recently issued research reports about the company. BMO Capital Markets assumed coverage on Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective on the stock. Wells Fargo & Company increased their target price on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Citigroup restated a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Truist Financial lifted their price target on Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday, July 16th. Finally, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $18.33.

Integra LifeSciences Trading Down 1.9%

Shares of IART opened at $18.89 on Friday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.26. The firm has a market cap of $1.47 billion, a price-to-earnings ratio of -2.92, a PEG ratio of 1.33 and a beta of 1.22. The firm has a 50 day moving average price of $17.01 and a 200-day moving average price of $13.13. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities research analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Several hedge funds and other institutional investors have recently modified their holdings of IART. Global Retirement Partners LLC purchased a new position in shares of Integra LifeSciences during the 4th quarter worth approximately $25,000. Osaic Holdings Inc. increased its stake in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Integra LifeSciences by 595.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Integra LifeSciences in the 4th quarter worth approximately $124,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.